As doubts con­tin­ue to fes­ter, In­ovio gets an­oth­er shove as Roche ex­its col­lab­o­ra­tion

Three years af­ter Roche signed up for a $422 mil­lion col­lab­o­ra­tion pact with In­ovio $INO on a pair of its ear­ly-stage de­vel­op­ment pro­grams, the phar­ma gi­ant is bow­ing out of the last re­main­ing ef­fort in the part­ner­ship. In­ovio says that it will take over the Phase I study for the he­pati­tis B vac­cine INO-1800, which is now fi­nal­ly en­rolling pa­tients.

Roche took con­sid­er­ably less time on INO-5150, its can­cer vac­cine. The com­pa­ny bowed out of that pro­gram in 2014. At the time, In­ovio had said it was start­ing a Phase I on 5150 in 2015. But ac­cord­ing to its pipeline chart, that’s where it still sits to­day.

Roche had kicked off the pre­clin­i­cal deal with a mod­est $10 mil­lion up­front.

CN­BC’s Melis­sa Lee and Meg Tir­rell with In­ovio CEO Joseph Kim.

In­ovio had pur­sued a fa­vorite PR ploy on both drugs, spot­light­ing what it claimed were re­mark­able an­i­mal da­ta that bode well for the hu­man tri­als to come. But over three years, there’s ev­i­dent­ly been lit­tle progress as the com­pa­ny con­tin­ues to ramp up new ef­forts for vac­cines against Ebo­la, Zi­ka and more.

In­ovio CEO Joseph Kim has come un­der fire for his fre­quent state­ments hyp­ing the com­pa­ny’s pro­grams and po­ten­tial. In a blunt show­down with CN­BC a lit­tle more than a month ago, two re­porters tried to get to the root of the trou­ble. But as I not­ed then, the ques­tions may have been tough, but the an­swers were all soft and fuzzy.

Spread too thin?

Kim: I think our pipeline is very full and very pro­duc­tive.

That yet-to-be-start­ed Phase III piv­otal study for cer­vi­cal dys­pla­sia. The Phase II was wrapped two years ago. Why the de­lay?

Kim: The FDA meet­ing was just a cou­ple of months ago, and be­sides, “it takes a long time to take new, dis­rup­tive tech­nolo­gies for these im­por­tant dis­eases for­ward.”

Our CN­BC Ebo­la in­ter­view oc­curred in No­vem­ber, 2014. Do you have the fund­ing and fo­cus nec­es­sary to com­plete the work?

Kim: There are 200 ded­i­cat­ed sci­en­tists and vac­cine de­vel­op­ers.

And lest any­one for­get: “The med­ical prod­uct de­vel­op­ment is a long and ar­du­ous road.”

The ever con­fi­dent Kim had this to say in a state­ment about 1800:

While we ac­knowl­edge Roche’s strate­gic de­ci­sion in the area of he­pati­tis B, we are op­ti­mistic that our po­tent im­munother­a­py plat­form will make a dif­fer­ence in this glob­al­ly im­por­tant chron­ic vi­ral in­fec­tion, sim­i­lar to what we have demon­strat­ed in HPV-re­lat­ed dis­ease. In­ovio was al­ready man­ag­ing the phase 1 clin­i­cal tri­al so the study will con­tin­ue on track with­out dis­rup­tion.

How Pa­tients with Epilep­sy Ben­e­fit from Re­al-World Da­ta

Amanda Shields, Principal Data Scientist, Scientific Data Steward

Keith Wenzel, Senior Business Operations Director

Andy Wilson, Scientific Lead

Real-world data (RWD) has the potential to transform the drug development industry’s efforts to predict and treat seizures for patients with epilepsy. Anticipating or controlling an impending seizure can significantly increase quality of life for patients with epilepsy. However, because RWD is secondary data originally collected for other purposes, the challenge is selecting, harmonizing, and analyzing the data from multiple sources in a way that helps support patients.

Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)

UP­DAT­ED: Gink­go Bioworks re­sizes the de­f­i­n­i­tion of go­ing big in biotech, rais­ing $2.5B in a record SPAC deal that weighs in with a whop­ping $15B-plus val­u­a­tion

Ginkgo Bioworks execs always thought big. But today should redefine just how big an upstart biotech player can dream.

In the largest SPAC deal to clear the hurdles to Nasdaq, the biotech that envisioned everything from remaking synthetic meat to a whole new approach to developing drugs has joined forces with one of the biggest disruptors in biotech to slam the Richter scale on dealmaking.

Soon after becoming the darling of the VC crew and clearing the bar on a $4 billion valuation, Ginkgo — a synthetic biotech player out to reprogram cells with industrial efficiency — has now struck a deal to go public in the latest leviathan SPAC that sets its pre-money valuation at $15 billion. In one swift vault, Ginkgo will combine with Harry Sloan’s Soaring Eagle Acquisition Corp. and leap into the public markets.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.

FDA un­veils six ICH guide­lines ahead of meet­ing with Health Cana­da

A sign that the FDA’s non-Covid-related processes are beginning to normalize: The release of six guidelines from the International Council of Harmonisation.

Years in development, the ICH documents offer an international perspective on drug development, with these latest guidelines covering everything from recommendations to support the classification of drug substances, featured in the M9 guidance, to standards for nonclinical safety studies for pediatric medicines in the S11 guideline.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Sanofi, Glax­o­SmithK­line, Boehringer ac­cused of play­ing games, de­stroy­ing emails re­lat­ed to law­suit over con­t­a­m­i­nat­ed Zan­tac

A recent court filing raises new questions about how major pharma companies like Sanofi, GlaxoSmithKline, and Boehringer Ingelheim have dealt with a lawsuit related to recalls of certain over-the-counter heartburn drugs due to the presence of a potentially cancer-causing substance found in them.

More than 70,000 people who took Sanofi’s Zantac and other heartburn drugs containing ranitidine, which have been recalled over the past two years, have sued the manufacturers, including generic drugmakers, and other retailers and distributors as part of a consolidated suit before US District Court Judge Robin Rosenberg in Florida.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.

Al Sandrock, Biogen R&D chief (Biogen via YouTube)

UP­DAT­ED: Bio­gen push­es in a fresh stack of chips and starts prep­ping a glob­al R&D game plan af­ter watch­ing the cards turn on ear­ly throm­bolyt­ic da­ta

After patiently steering through a decade-long journey for its early-stage clinical work, a small Tokyo biotech has clinched a deal to out-license its lead thrombolytic agent to US heavyweight Biogen — which sees a potentially game-changing impact on the clot-busting field after taking a careful look at some upbeat Phase IIa data.

Three years after Biogen anted up $4 million to gain an option on the drug from TMS, the big US biotech is making a small bet to beef up its stroke portfolio. The BD team inked a deal to go ahead and grab rights to the drug for $18 million, with another $335 million in milestone cash on the table for a successful outcome.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.

Chris Garabedian (Xontogeny)

Per­cep­tive Ad­vi­sors, Xon­toge­ny bring the band back and then some with a $515M sec­ond fund sniff­ing out lead com­pounds

When Perceptive Advisors and startup accelerator Xontogeny initially teamed up on an early-stage VC round in 2019, the partners hoped to prove their investments could be a force multiplier for early-stage companies. Now, with that proof of concept behind them, the pair have closed a second VC round worth more than double the money.

Dubbed PXV Fund II and headed by Xontogeny CEO and former Sarepta head Chris Garabedian, the $515 million fund will target 10 to 12 early-stage preclinical companies with Series A rounds in the $20 million to $40 million range with opportunities for Series B follow-ups. The oversubscribed fund is bringing the band back with initial investors from PXVI as well as new investors that include “top-tier” asset managers, endowments, foundations, family offices, and individual investors.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.

A clos­er look at the FDA’s more than 700 pan­dem­ic-re­lat­ed record re­quests to re­place on­site in­spec­tions

As the pandemic constrained the FDA’s ability to travel for onsite manufacturing inspections, the agency increasingly turned to requesting records to fill the gap, even for hundreds of US-based facilities.

FDA explains in its guidance on manufacturing inspections during the pandemic that the agency can request records (not to be confused with the FDA’s remote interactive evaluations) directly from facilities “in advance of or in lieu of” certain onsite inspections. Companies are legally required to fulfill those requests because a denial may be considered limiting an inspection, which could lead to the FDA deeming a drug made at that site to be adulterated.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Stephen Squinto, Gennao Bio CEO (Gennao)

Alex­ion co-founder Stephen Squin­to is back in the game as CEO, this time for a small gene ther­a­py play­er

With his name already behind a rare disease success story in Alexion, Stephen Squinto was looking for a great story to drive him to jump back into the biotech game. He found that in a fledging non-viral gene therapy company, and now he’s got a few backers on board as well.

On Tuesday, Gennao Bio launched with a $40 million Series A co-led by OrbiMed and Logos Capital with participation by Surveyor Capital. The biotech, which is looking to use its cell-penetrating antibody platform to deliver nucleic acid “payloads” during into the nucleus, had to rush for its initial series — and had a name change along the way.

Distribution of Moderna's Covid-19 Vaccine (Photo by Paul Sancya - Pool/Getty Images)

Opin­ion: Ado­les­cents can wait. The US needs to start do­nat­ing Covid-19 vac­cines to needy coun­tries now.

Now that the US is swimming in Covid-19 vaccines and the supply has officially eclipsed the demand, it’s time for America to lead the world and start shipping these excess doses to countries that desperately need them.

Unlike the IP waiver at the World Trade Organization, which Biden now supports and will likely take years to translate into actual shots in arms, the US could easily donate just a tiny fraction of the more than 60 million doses of Pfizer, Moderna and J&J vaccines sitting on American shelves right now.